Tohoku University

Fate Therapeutics' FT825 Shows Promise in HER2-Targeting CAR T-Cell Therapy for Solid Tumors

6 months ago

• Fate Therapeutics presented initial Phase 1 data for FT825 / ONO-8250, a HER2-targeting CAR T-cell therapy, showing a favorable safety profile in advanced solid tumors. • Preclinical data highlights FT825's cancer-selective HER2 recognition, potentially reducing off-target toxicities compared to existing HER2-directed therapies. • The Phase 1 study observed CAR T-cell expansion and activation in patients' peripheral blood, indicating potential for effective tumor targeting. • FT825 incorporates novel synthetic controls designed to enhance safety and efficacy in treating solid tumors, addressing limitations of current CAR T-cell therapies.

Fate Therapeutics Presents Promising Early Data for FT825/ONO-8250 CAR-T Therapy in Solid Tumors

6 months ago

• Fate Therapeutics' FT825/ONO-8250, a HER2-targeting CAR-T cell therapy, shows a favorable safety profile in an early-stage trial for advanced solid tumors. • Preclinical data highlights the therapy's cancer-selective HER2 targeting, reducing off-tumor toxicities compared to traditional HER2-directed treatments. • Initial results from the Phase 1 study indicate CAR T-cell expansion and activation in patients, suggesting potential for clinical efficacy. • The FT825 / ONO-8250 incorporates seven novel synthetic controls of CAR T-cell function designed to overcome multiple mechanisms.